Coronavirus Update: After Rumors Of Shortcut To Market, AZ Pledges To ‘Follow Science’ In Vaccine Trials
Plus: Moderna Confirms Japan Vaccine Supply Discussions
Executive Summary
The company reiterates core values to 'follow the science' and 'put patients first' after talk of an emergency use authorization without completing Phase III trials.
You may also be interested in...
Deciphering Bangladesh’s Agile Supply Deal For AZ/Serum Vaccine
Senior Beximco executive outlines details, including pricing nuances, of a deal with the Serum Institute of India for the supply to Bangladesh of the AstraZeneca/University of Oxford coronavirus vaccine. Will India’s neighbor also benefit from pricing adjustments?
Gottlieb: Staged Access To Coronavirus Vaccine Possible Through EUA
Former FDA Commissioner says agency could grant an EUA for a vaccine, but require it meet the standard for full approval, and then roll it out gradually with postmarket data collection.
Pfizer CEO: Vaccine Could Be Ready In October But Won't Be Hurried By Political Pressure
Bourla reassures on scientific integrity amid fears of a politically motivated Emergency Use Authorization.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports